AVI Biopharma, Inc.

Corvallis, OR 97333

SBIR Award Summary

Total Number of Awards 11
Total Value of Awards $3.18MM
First Award Date 09/30/98
Most Recent Award Date 08/01/09

Key Personnel

Last Name Name Awards Contact
Iversen Patrick L. Iversen 3
Porter Thomas R Porter 2
Bourne Nigel Bourne 1
Devi Gayathri R Devi 2
Mourich Dan V Mourich 1
Sazani Peter Sazani 2

11 Awards Won

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-281
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): The ultimate goal of this project, development of an anti-TNF-1 drug for rheumatoid arthritis and/or other TNF-1 induced inflammatory diseases, remains unchanged from the original application. The Phase II project will build on the Phase I identification of a locked nucleic acid, splice switching oligonucleot...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-07-81
Budget: 07/01/09 - 07/31/09

DESCRIPTION (provided by applicant): The ultimate goal of this project, development of an anti-TNF-1 drug for rheumatoid arthritis and/or other TNF-1 induced inflammatory diseases, remains unchanged from the original application. The Phase II project will build on the Phase I identification of a locked nucleic acid, splice switching oligonucleot...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 05/01/05 - 04/30/07

DESCRIPTION (provided by applicant): AVI BioPharma has been developing an antisense phosphorodiamidate morpholino oligomer, AVI-4020 for the treatment of West Nile Virus. AVI-4020 has been shown both to reduce viral titer, and to cross the blood brain barrier. This compound targets the translation start site of the single open reading frame of W...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 02/01/05 - 01/31/06

DESCRIPTION (provided by applicant): The response of lymphocytes to antigen stimulation is characterized by proliferation of an antigen-sensitive lymphocyte population, subsequent differentiation to subsets with effector cell function, and ultimately the retention of antigen-responsive lymphocytes with a memory cell phenotype. The initial increa...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 07/31/07

DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinoma. Although the annual number of newly infected patients has dropped significantly over the past decade, about 4 million people are currently persi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 09/29/05

DESCRIPTION (provided by applicant): The broad, long-term objectives of the application are to develop antisense inhibitors of retinopathy and document their mechanism(s) of action. Retinopathy is a significant cause of eye disease and has a major impact on development, learning, communicating, working, health, and quality of life for affected i...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 02/19/03 - 01/31/05

DESCRIPTION (provided by applicant): Prostate cancer is the second leading cause of cancer death in US men. Prostate cancer is highly dependent on androgen stimulation mediated through the androgen receptor (AR) for growth and proliferation. For those with advanced PCa, androgen ablation remains the foundation of therapy. Current methods of a...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/03

The long term objective of this project is to utilize the multiple therapeutic properties of perfluorocarbon containing albumin coated microbubbles to non-invasively target synthetic gene therapy and recanalize thrombosed access grafts and coronary arteries. The ability of intravenous perfluorocarbon containing albumin microbubbles to bind and d...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/00 - 08/31/01

The long term objective of this project is to utilize the multiple therapeutic properties of perfluorocarbon containing albumin coated microbubbles to non-invasively target synthetic gene therapy and recanalize thrombosed access grafts and coronary arteries. The ability of intravenous perfluorocarbon containing albumin microbubbles to bind and d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/00 - 06/30/01

Development of a drug therapy to treat polycystic kidney disease (PKD) is proposed. PKD is the most common human genetic disease affecting approximately one half million people in the USA. The over-expression of the proto-oncogene c-myc has been shown to be integral to cyst development in rodent PKD models which mimic the human disease. We pro...

Load More